Streptococcus pneumoniae: Does Antimicrobial Resistance Matter?

ABSTRACT

Over the past 3 decades, antimicrobial resistance among Streptococcus pneumoniae, the most common cause of community-acquired pneumonia (CAP), has escalated dramatically worldwide. In the late 1970s, strains of pneumococci displaying resistance to penicillin were described in South Africa and Spain. By the early 1990s, penicillin-resistant clones of S. pneumoniae spread rapidly across Europe and globally. Additionally, resistance to macrolides and other antibiotic classes escalated in tandem with penicillin resistance. Six international clones (serotypes 6A, 6B, 9V, 14, 19F, 23F) were responsible for most of these resistant isolates. Currently, 15 to 30% of S. pneumoniae worldwide are multidrug-resistant (MDR) (i.e., resistant to ≥ 3 classes of antibiotics). Despite the dramatic escalation in the rate of antimicrobial resistance among pneumococci worldwide, the clinical impact of antimicrobial resistance is difficult to define. Treatment failures due to antibiotic-resistant pneumococci have been reported with meningitis, otitis media, and lower respiratory tract infections, but the relation between drug resistance and treatment failures has not been convincingly established. Clinical failures often reflect factors independent of antimicrobial susceptibility of the infecting organisms. Host factors (e.g., extremes of age; underlying immunosuppressive or debilitating disease; comorbidities), or factors that affect intrinsic virulence of the organisms (e.g., capsular subtype) strongly influence prognosis. Mortality rates are higher in the presence of: multilobar involvement, renal insufficiency, need for intensive care unit (ICU) care, hypoxemia, severe derangement in physiological parameters, and comorbidities. Given these confounding factors, dissecting out the impact of antimicrobial resistance on clinical outcomes is difficult, if not impossible. Prospective, randomized trials designed to assess the clinical significance of antimicrobial resistance among pneumococci are lacking, and for logistical reasons, will never be done. Does in vitro resistance translate into clinical failures? Should changing resistance patterns modify our choice of therapy for CAP or for suspected pneumococcal pneumonia? In this review, we discuss several facets, including mechanisms of antimicrobial resistance among specific antibiotic classes, epidemiology and spread of antimicrobial resistance determinants regionally and worldwide, risk factors for acquisition and dissemination of resistance, the impact of key international clones displaying multidrug resistance, the clinical impact of antimicrobial resistance, and strategies to limit or curtail antimicrobial resistance among this key respiratory tract pathogen.

Streptococcus pneumoniae - pneumococcus - invasive pneumococcal disease (IPD) - antimicrobial resistance - penicillin resistance - macrolide resistance

REFERENCES

• 1 Klugman K P. Pneumococcal resistance to antibiotics.  Clin Microbiol Rev. 1990;  3 171-196
• 2 Appelbaum P C. Antimicrobial resistance in Streptococcus pneumoniae: an overview.  Clin Infect Dis. 1992;  15 77-83
• 3 Doern G V, Richter S S, Miller A et al.. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?.  Clin Infect Dis. 2005;  41 139-148
• 4 Lynch III J P, Zhanel G G. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.  Semin Respir Crit Care Med. 2005;  26 575-616
• 5 Jacobs M R, Koornhof H J, Robins-Browne R M et al.. Emergence of multiply resistant pneumococci.  N Engl J Med. 1978;  299 735-740
• 6 Hsieh Y C, Hsueh P R, Lu C Y, Lee P I, Lee C Y, Huang L M. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by Streptococcus pneumoniae in children in Taiwan.  Clin Infect Dis. 2004;  38 830-835
• 7 Doern G V, Heilmann K P, Huynh H K, Rhomberg P R, Coffman S L, Brueggemann A B. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995.  Antimicrob Agents Chemother. 2001;  45 1721-1729
• 8 Gherardi G, Fallico L, Del Grosso M et al.. Antibiotic-resistant invasive pneumococcal clones in Italy.  J Clin Microbiol. 2007;  45 306-312
• 9 Farrell D J, Jenkins S G, Brown S D, Patel M, Lavin B S, Klugman K P. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance.  Emerg Infect Dis. 2005;  11 851-858
• 10 Richter S S, Heilmann K P, Coffman S L et al.. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994–2000.  Clin Infect Dis. 2002;  34 330-339
• 11 Granizo J J, Aguilar L, Casal J, Garcia-Rey C, Dal-Re R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979–1997).  J Antimicrob Chemother. 2000;  46 767-773
• 12 Gay K, Baughman W, Miller Y et al.. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment.  J Infect Dis. 2000;  182 1417-1424
• 13 Corso A, Severina E P, Petruk V F, Mauriz Y R, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States.  Microb Drug Resist. 1998;  4 325-337
• 14 Widdowson C A, Klugman K P. Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa.  Emerg Infect Dis. 1998;  4 277-281
• 15 Kresken M, Henrichfreise B, Bagel S, Brauers J, Wiedemann B. High prevalence of the ermB gene among erythromycin-resistant Streptococcus pneumoniae isolates in Germany during the winter of 2000–2001 and in vitro activity of telithromycin.  Antimicrob Agents Chemother. 2004;  48 3193-3195
• 16 Brown S D, Farrell D J, Morrissey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000–2001 PROTEKT US Study.  J Clin Microbiol. 2004;  42 4980-4987
• 17 Alou L, Ramirez M, Garcia-Rey C, Prieto J, de Lencastre H. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones.  Antimicrob Agents Chemother. 2001;  45 2955-2957
• 18 Nichol K A, Zhanel G G, Hoban D J. Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada.  Antimicrob Agents Chemother. 2003;  47 804-808
• 19 Johnson C N, Benjamin Jr Jr W H, Moser S A et al.. Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America.  J Clin Microbiol. 2003;  41 2458-2464
• 20 Davies T A, Goldschmidt R, Pfleger S et al.. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998–2000).  J Antimicrob Chemother. 2003;  52 168-175
• 21 Weiss K, Restieri C, Gauthier R et al.. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae .  Clin Infect Dis. 2001;  33 517-522
• 22 de la Campa A G, Balsalobre L, Ardanuy C, Fenoll A, Perez-Trallero E, Linares J. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.  Emerg Infect Dis. 2004;  10 1751-1759
• 23 Pletz M W, McGee L, Jorgensen J et al.. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.  Antimicrob Agents Chemother. 2004;  48 3491-3497
• 24 Vilhelmsson S E, Kristinsson K G. Stability of penicillin-susceptible and nonsusceptible clones of Streptococcus pneumoniae in southern Sweden.  Microb Drug Resist. 2007;  13 108-113
• 25 Marimon J M, Perez-Trallero E, Ercibengoa M, Gonzalez A, Fenoll A. Molecular epidemiology and variants of the multidrug-resistant Streptococcus pneumoniae Spain14–5 international clone among Spanish clinical isolates.  J Antimicrob Chemother. 2006;  57 654-660
• 26 Vanderkooi O G, Low D E, Green K, Powis J E, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections.  Clin Infect Dis. 2005;  40 1288-1297
• 27 Riedel S, Beekmann S E, Heilmann K P et al.. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae .  Eur J Clin Microbiol Infect Dis. 2007;  26 485-490
• 28 Albrich W C, Monnet D L, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes .  Emerg Infect Dis. 2004;  10 514-517
• 29 Syrogiannopoulos G A, Grivea I N, Davies T A, Katopodis G D, Appelbaum P C, Beratis N G. Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the first 2 years of life.  Clin Infect Dis. 2000;  31 887-893
• 30 Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?.  J Chemother. 1999;  11(Suppl 1) 35-43
• 31 Cizman M, Pokorn M, Seme K, Paragi M, Orazem A. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens.  Eur J Clin Microbiol Infect Dis. 1999;  18 522-524
• 32 Pihlajamaki M, Kotilainen P, Kaurila T, Klaukka T, Palva E, Huovinen P. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents.  Clin Infect Dis. 2001;  33 483-488
• 33 Chen D K, McGeer A, de Azavedo J C, Low D E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.  N Engl J Med. 1999;  341 233-239
• 34 Bhavnani S M, Hammel J P, Jones R N, Ambrose P G. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.  Diagn Microbiol Infect Dis. 2005;  51 31-37
• 35 Van Eldere J, Mera R M, Miller L A, Poupard J A, Amrine-Madsen H. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location.  Antimicrob Agents Chemother. 2007;  51 3491-3497
• 36 Bergman M, Huikko S, Huovinen P, Paakkari P, Seppala H. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2006;  50 3646-3650
• 37 Livermore D M, Reynolds R, Stephens P et al.. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors.  Int J Antimicrob Agents. 2006;  28 273-279
• 38 Raz R, Elhanan G, Shimoni Z et al.. Pneumococcal bacteremia in hospitalized Israeli adults: epidemiology and resistance to penicillin. Israeli Adult Pneumococcal Bacteremia Group.  Clin Infect Dis. 1997;  24 1164-1168
• 39 Mufson M A, Stanek R J. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997.  Am J Med. 1999;  107(1A) 34S-43S
• 40 Rahav G, Toledano Y, Engelhard D et al.. Invasive pneumococcal infections: a comparison between adults and children.  Medicine (Baltimore). 1997;  76 295-303
• 41 Waterer G W, Buckingham S C, Kessler L A, Quasney M W, Wunderink R G. Decreasing beta-lactam resistance in pneumococci from the Memphis region: analysis of 2,152 isolates From 1996 to 2001.  Chest. 2003;  124 519-525
• 42 Catalan M J, Fernandez J M, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo de Quiros J C. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae .  Clin Infect Dis. 1994;  18 766-769
• 43 Sloas M M, Barrett F F, Chesney P J et al.. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis.  Pediatr Infect Dis J. 1992;  11 662-666
• 44 Dagan R, Abramson O, Leibovitz E et al.. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media?.  J Infect Dis. 1997;  176 1253-1259
• 45 del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain.  Pediatr Infect Dis J. 1998;  17 94-97
• 46 Jacobs M R. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media.  Pediatr Infect Dis J. 1996;  15 940-943
• 47 Poole M D. Otitis media complications and treatment failures: implications of pneumococcal resistance.  Pediatr Infect Dis J. 1995;  14(4, Suppl) S23-S26
• 48 Feikin D R, Schuchat A, Kolczak M et al.. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997.  Am J Public Health. 2000;  90 223-229
• 49 Metlay J P, Hofmann J, Cetron M S et al.. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2000;  30 520-528
• 50 Pallares R, Gudiol F, Linares J et al.. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci.  N Engl J Med. 1987;  317 18-22
• 51 Pallares R, Linares J, Vadillo M et al.. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.  N Engl J Med. 1995;  333 474-480
• 52 Yu V L, Chiou C C, Feldman C et al.. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.  Clin Infect Dis. 2003;  37 230-237
• 53 Lynch III J P, Martinez F J. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.  Clin Infect Dis. 2002;  34(Suppl 1) S27-S46
• 54 Waterer G W, Wunderink R G, Jones C B. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.  Chest. 2000;  118 1839-1840
• 55 Kelley M A, Weber D J, Gilligan P, Cohen M S. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.  Clin Infect Dis. 2000;  31 1008-1011
• 56 Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin.  Clin Infect Dis. 2000;  31 613-615
• 57 Lonks J R. What is the clinical impact of macrolide resistance?.  Curr Infect Dis Rep. 2004;  6 7-12
• 58 Low D E. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.  Clin Infect Dis. 2004;  38(Suppl 4) S357-S362
• 59 Low D E. Fluoroquinolone-resistant pneumococci: maybe resistance isn't futile?.  Clin Infect Dis. 2005;  40 236-238
• 60 Davidson R, Cavalcanti R, Brunton J L et al.. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  346 747-750
• 61 Urban C, Rahman N, Zhao X et al.. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.  J Infect Dis. 2001;  184 794-798
• 62 Aspa J, Rajas O, Rodriguez de Castro F et al.. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.  Clin Infect Dis. 2004;  38 787-798
• 63 Henriques B, Kalin M, Ortqvist A et al.. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries.  J Infect Dis. 2000;  182 833-839
• 64 Song J H, Jung S I, Ki H K et al.. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens.  Clin Infect Dis. 2004;  38 1570-1578
• 65 Friedland I R. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease.  Pediatr Infect Dis J. 1995;  14 885-890
• 66 Baddour L M, Yu V L, Klugman K P et al.. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.  Am J Respir Crit Care Med. 2004;  170 440-444
• 67 Turett G S, Blum S, Fazal B A, Justman J E, Telzak E E. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence.  Clin Infect Dis. 1999;  29 321-327
• 68 Neuman M I, Kelley M, Harper M B, File Jr T M, Camargo Jr C A. Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia.  J Emerg Med. 2007;  32 349-357
• 69 Ewig S, Ruiz M, Torres A et al.. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae .  Am J Respir Crit Care Med. 1999;  159 1835-1842
• 70 Karlowsky J A, Thornsberry C, Jones M E, Evangelista A T, Critchley I A, Sahm D F. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998–2002).  Clin Infect Dis. 2003;  36 963-970
• 71 Johnson C N, Briles D E, Benjamin Jr W H, Hollingshead S K, Waites K B. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae .  Emerg Infect Dis. 2005;  11 814-820
• 72 Smith A M, Feldman C, Massidda O, McCarthy K, Ndiweni D, Klugman K P. Altered PBP 2A and its role in the development of penicillin, cefotaxime, and ceftriaxone resistance in a clinical isolate of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2005;  49 2002-2007
• 73 National Committee for Clinical Laboratory Standards .Performance standards for antimicrobial susceptibility testing. Tenth informational supplement, M100–S11. Wayne, PA; National Committee for Clinical Laboratory Standards 2001
• 74 Kosowska K, Jacobs M R, Bajaksouzian S, Koeth L, Appelbaum P C. Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs.  Antimicrob Agents Chemother. 2004;  48 4020-4022
• 75 Jacobs M R, Felmingham D, Appelbaum P C, Gruneberg R N. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.  J Antimicrob Chemother. 2003;  52 229-246
• 76 Sahm D F, Thornsberry C, Mayfield D C, Jones M E, Karlowsky J A. In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100–S12 recommendations.  J Clin Microbiol. 2002;  40 669-674
• 77 Ruhe J J, Myers L, Mushatt D, Hasbun R. High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup.  Clin Infect Dis. 2004;  38 508-514
• 78 Appelbaum P C. World-wide development of antibiotic resistance in pneumococci.  Eur J Clin Microbiol. 1987;  6 367-377
• 79 Appelbaum P C. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae .  Pediatr Infect Dis J. 1996;  15 932-934
• 80 Bedos J P, Chevret S, Chastang C, Geslin P, Regnier B. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey.  Clin Infect Dis. 1996;  22 63-72
• 81 Kam K M, Luey K Y, Fung S M, Yiu P P, Harden T J, Cheung M M. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong.  Antimicrob Agents Chemother. 1995;  39 2667-2670
• 82 Lee H J, Park J Y, Jang S H, Kim J H, Kim E C, Choi K W. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea.  Clin Infect Dis. 1995;  20 826-835
• 83 Song J H, Lee N Y, Ichiyama S et al.. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study.  Clin Infect Dis. 1999;  28 1206-1211
• 84 Doern G V, Brueggemann A, Holley Jr H P, Rauch A M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.  Antimicrob Agents Chemother. 1996;  40 1208-1213
• 85 Doern G V, Brueggemann A B, Blocker M et al.. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States.  Clin Infect Dis. 1998;  27 757-761
• 86 Doern G V, Brueggemann A B, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.  Emerg Infect Dis. 1999;  5 757-765
• 87 Whitney C G, Farley M M, Hadler J et al.. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.  N Engl J Med. 2000;  343 1917-1924
• 88 Thornsberry C, Jones M E, Hickey M L, Mauriz Y, Kahn J, Sahm D F. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997–1998.  J Antimicrob Chemother. 1999;  44 749-759
• 89 Deeks S L, Palacio R, Ruvinsky R et al.. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group.  Pediatrics. 1999;  103 409-413
• 90 Schrag S J, McGee L, Whitney C G et al.. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin.  Antimicrob Agents Chemother. 2004;  48 3016-3023
• 91 Zhanel G G, Palatnick L, Nichol K A, Bellyou T, Low D E, Hoban D J. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.  Antimicrob Agents Chemother. 2003;  47 1867-1874
• 92 Pallares R, Capdevila O, Linares J et al.. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections.  Am J Med. 2002;  113 120-126
• 93 Karlowsky J A, Jones M E, Draghi D C, Sahm D F. Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime.  Antimicrob Agents Chemother. 2003;  47 3155-3160
• 94 Smith A M, Klugman K P. Alterations in MurM, a cell wall muropeptide branching enzyme, increase high-level penicillin and cephalosporin resistance in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2001;  45 2393-2396
• 95 Munoz R, Dowson C G, Daniels M et al.. Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae .  Mol Microbiol. 1992;  6 2461-2465
• 96 Doern G V, Pfaller M A, Kugler K, Freeman J, Jones R N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program.  Clin Infect Dis. 1998;  27 764-770
• 97 Nichol K A, Zhanel G G, Hoban D J. Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2002;  46 3261-3264
• 98 du Plessis M, Bingen E, Klugman K P. Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin.  Antimicrob Agents Chemother. 2002;  46 2349-2357
• 99 Coffey T J, Daniels M, McDougal L K, Dowson C G, Tenover F C, Spratt B G. Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins.  Antimicrob Agents Chemother. 1995;  39 1306-1313
• 100 Chiu C H, Su L H, Huang Y C et al.. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan.  Antimicrob Agents Chemother. 2007;  51 3404-3406
• 101 McDougal L K, Rasheed J K, Biddle J W, Tenover F C. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States.  Antimicrob Agents Chemother. 1995;  39 2282-2288
• 102 Waites K, Brown S. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001.  South Med J. 2003;  96 974-985
• 103 Karlowsky J A, Thornsberry C, Critchley I A et al.. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000–2001 and 2001–2002 TRUST studies in the United States.  Antimicrob Agents Chemother. 2003;  47 1790-1797
• 104 Jones M E, Blosser-Middleton R S, Thornsberry C, Karlowsky J A, Sahm D F. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999–2002.  Diagn Microbiol Infect Dis. 2003;  47 579-586
• 105 Dias R, Louro D, Canica M. Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.  Antimicrob Agents Chemother. 2006;  50 2098-2105
• 106 Song J H, Jung S I, Ko K S et al.. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).  Antimicrob Agents Chemother. 2004;  48 2101-2107
• 107 Brandileone M C, Casagrande S T, Guerra M L, Zanella R C, Andrade A L, Di Fabio J L. Increase in numbers of beta-lactam-resistant invasive Streptococcus pneumoniae in Brazil and the impact of conjugate vaccine coverage.  J Med Microbiol. 2006;  55(Pt 5) 567-574
• 108 Critchley I A, Brown S D, Traczewski M M, Tillotson G S, Janjic N. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005–2006 U.S. Faropenem surveillance study.  Antimicrob Agents Chemother. 2007;  51 4382-4389
• 109 Zhanel G G, Wang X, Nichol K et al.. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998–2004.  Int J Antimicrob Agents. 2006;  28 465-471
• 110 Finkelstein J A, Huang S S, Daniel J et al.. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample.  Pediatrics. 2003;  112 862-869
• 111 Nuorti J P, Butler J C, Crutcher J M et al.. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents.  N Engl J Med. 1998;  338 1861-1868
• 112 Nava J M, Bella F, Garau J et al.. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study.  Clin Infect Dis. 1994;  19 884-890
• 113 Choi E H, Lee H J. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children.  Clin Infect Dis. 1998;  26 1346-1354
• 114 Koornhof H J, Wasas A, Klugman K. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective.  Clin Infect Dis. 1992;  15 84-94
• 115 Albanese B A, Roche J C, Pass M, Whitney C G, McEllistrem M C, Harrison L H. Geographic, demographic, and seasonal differences in penicillin-resistant Streptococcus pneumoniae in Baltimore.  Clin Infect Dis. 2002;  34 15-21
• 116 Hofmann J, Cetron M S, Farley M M et al.. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta.  N Engl J Med. 1995;  333 481-486
• 117 Crewe-Brown H H, Karstaedt A S, Saunders G L et al.. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes.  Clin Infect Dis. 1997;  25 1165-1172
• 118 Pemba L, Charalambous S, von Gottberg A et al.. Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa.  J Infect. 2008;  56 171-178
• 119 Meynard J L, Barbut F, Blum L et al.. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus.  Clin Infect Dis. 1996;  22 437-440
• 120 Sa-Leao R, Tomasz A, Sanches I S et al.. Carriage of internationally spread clones of Streptococcus pneumoniae with unusual drug resistance patterns in children attending day care centers in Lisbon, Portugal.  J Infect Dis. 2000;  182 1153-1160
• 121 Ronchetti M P, Guglielmi F, Latini L et al.. Resistance patterns of Streptococcus pneumoniae from children in central Italy.  Eur J Clin Microbiol Infect Dis. 1999;  18 376-379
• 122 Brueggemann A B, Coffman S L, Rhomberg P et al.. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994–1995.  Antimicrob Agents Chemother. 2002;  46 680-688
• 123 Hamilton-Miller J M, Shah S. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status.  J Antimicrob Chemother. 1998;  41 649-653
• 124 Jalava J, Kataja J, Seppala H, Huovinen P. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.  Antimicrob Agents Chemother. 2001;  45 789-793
• 125 Reinert R R, Bryskier A, Lutticken R. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.  Antimicrob Agents Chemother. 1998;  42 1509-1511
• 126 Marton A. Pneumococcal antimicrobial resistance: the problem in Hungary.  Clin Infect Dis. 1992;  15 106-111
• 127 Mason Jr E O, Lamberth L B, Kershaw N L, Prosser B L, Zoe A, Ambrose P G. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis.  J Antimicrob Chemother. 2000;  45 623-631
• 128 Latini L, Ronchetti M P, Merolla R et al.. Prevalence of mefE, erm and tet(M) genes in Streptococcus pneumoniae strains from Central Italy.  Int J Antimicrob Agents. 1999;  13 29-33
• 129 Arrieta A, Arguedas A, Fernandez P et al.. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.  Antimicrob Agents Chemother. 2003;  47 3179-3186
• 130 Reichler M R, Rakovsky J, Slacikova M et al.. Spread of multidrug-resistant Streptococcus pneumoniae among hospitalized children in Slovakia.  J Infect Dis. 1996;  173 374-379
• 131 Moreno S, Garcia-Leoni M E, Cercenado E, Diaz M D, Bernaldo de Quiros J C, Bouza E. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study.  Clin Infect Dis. 1995;  20 1195-1200
• 132 Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season. The Laboratory Investigator Group.  Diagn Microbiol Infect Dis. 1997;  29 249-257
• 133 Hoban D J, Doern G V, Fluit A C, Roussel-Delvallez M, Jones R N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999.  Clin Infect Dis. 2001;  32(Suppl 2) S81-S93
• 134 Farrell D J, Morrissey I, Bakker S, Buckridge S, Felmingham D. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.  Antimicrob Agents Chemother. 2004;  48 3169-3171
• 135 Brown S D, Farrell D J. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001–2002.  J Antimicrob Chemother. 2004;  54(Suppl 1) i23-i29
• 136 Felmingham D, Reinert R R, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin.  J Antimicrob Chemother. 2002;  50(Suppl S1) 25-37
• 137 Powis J, McGeer A, Green K et al.. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.  Antimicrob Agents Chemother. 2004;  48 3305-3311
• 138 Hsueh P R, Teng L J, Wu T L et al.. Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.  Antimicrob Agents Chemother. 2003;  47 2145-2151
• 139 Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C et al.. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998–1999) multicenter surveillance study in Spain.  Antimicrob Agents Chemother. 2001;  45 3334-3340
• 140 Castanheira M, Gales A C, Mendes R E, Jones R N, Sader H S. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program.  Clin Microbiol Infect. 2004;  10 645-651
• 141 Mendes C, Kiffer C R, Blosser-Middleton R S et al.. Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001–2002.  Clin Microbiol Infect. 2004;  10 521-526
• 142 Johnson D M, Stilwell M G, Fritsche T R, Jones R N. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003).  Diagn Microbiol Infect Dis. 2006;  56 69-74
• 143 Doit C, Loukil C, Fitoussi F, Geslin P, Bingen E. Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin.  Antimicrob Agents Chemother. 1999;  43 1480-1483
• 144 Schito G C, Debbia E A, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project.  J Antimicrob Chemother. 2000;  46(Suppl T1) 3-9
• 145 Reinert R R, Lutticken R, Bryskier A, Al-Lahham A. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000–2001.  Antimicrob Agents Chemother. 2003;  47 489-493
• 146 Backhaus E, Berg S, Trollfors B et al.. Antimicrobial susceptibility of invasive pneumococcal isolates from a region in south-west Sweden 1998–2001.  Scand J Infect Dis. 2007;  39 19-27
• 147 Schito G C, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999–2003).  Int J Antimicrob Agents. 2005;  26 479-485
• 148 Monaco M, Camilli R, D'Ambrosio F, Del Grosso M, Pantosti A. Evolution of erythromycin resistance in Streptococcus pneumoniae in Italy.  J Antimicrob Chemother. 2005;  55 256-259
• 149 Marchese A, Gualco L, Cochetti I et al.. Antibiotic susceptibility and serotype distribution in Streptococcus pneumoniae circulating in Italy: results of the SEMPRE surveillance study (2000–2002).  Int J Antimicrob Agents. 2005;  26 138-145
• 150 Ho P, Yuen K, Yam W, Sai-yin Wong S, Luk W. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong.  J Hosp Infect. 1995;  31 305-317
• 151 Ho P L, Que T L, Tsang D N, Ng T K, Chow K H, Seto W H. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.  Antimicrob Agents Chemother. 1999;  43 1310-1313
• 152 Valles X, Marcos A, Pinart M et al.. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: has resistance to antibiotics decreased?.  Chest. 2006;  130 800-806
• 153 Benbachir M, Benredjeb S, Boye C S et al.. Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities.  Antimicrob Agents Chemother. 2001;  45 627-629
• 154 Joloba M L, Bajaksouzian S, Palavecino E, Whalen C, Jacobs M R. High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.  Int J Antimicrob Agents. 2001;  17 395-400
• 155 Ramdani-Bouguessa N, Rahal K. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolated in Algiers, Algeria.  Antimicrob Agents Chemother. 2003;  47 824-826
• 156 Adegbola R A, Hill P C, Secka O et al.. Serotype and antimicrobial susceptibility patterns of isolates of Streptococcus pneumoniae causing invasive disease in The Gambia 1996–2003.  Trop Med Int Health. 2006;  11 1128-1135
• 157 Sener B, Tunckanat F, Ulusoy S et al.. A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004 2005.  J Antimicrob Chemother. 2007;  60 587-593
• 158 Gur D, Ozalp M, Sumerkan B et al.. Prevalence of antimicrobial resistance in Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Streptococcus pyogenes: results of a multicentre study in Turkey.  Int J Antimicrob Agents. 2002;  19 207-211
• 159 Heffernan H M, Martin D R, Woodhouse R E, Morgan J, Blackmore T K. Invasive pneumococcal disease in New Zealand 1998–2005: capsular serotypes and antimicrobial resistance.  Epidemiol Infect. 2008;  136 352-359
• 160 Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN).  Lancet. 1999;  353 1216-1221
• 161 Saha S K, Rikitomi N, Ruhulamin M et al.. Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae strains causing childhood infections in Bangladesh, 1993 to 1997.  J Clin Microbiol. 1999;  37 798-800
• 162 Noguchi N, Tano J, Nasu Y et al.. Antimicrobial susceptibilities and distribution of resistance genes for beta-lactams and macrolides in Streptococcus pneumoniae isolated between 2002 and 2004 in Tokyo.  Int J Antimicrob Agents. 2007;  29 26-33
• 163 Lau Y J, Hsueh P R, Liu Y C et al.. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan.  Microb Drug Resist. 2006;  12 130-135
• 164 Spika J S, Facklam R R, Plikaytis B D, Oxtoby M J. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979–1987. The Pneumococcal Surveillance Working Group.  J Infect Dis. 1991;  163 1273-1278
• 165 Jorgensen J H, Doern G V, Maher L A, Howell A W, Redding J S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.  Antimicrob Agents Chemother. 1990;  34 2075-2080
• 166 Breiman R F, Butler J C, Tenover F C, Elliott J A, Facklam R R. Emergence of drug-resistant pneumococcal infections in the United States.  JAMA. 1994;  271 1831-1835
• 167 Butler J C, Hofmann J, Cetron M S, Elliott J A, Facklam R R, Breiman R F. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.  J Infect Dis. 1996;  174 986-993
• 168 Sahm D F, Jones M E, Hickey M L, Diakun D R, Mani S V, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997–1998.  J Antimicrob Chemother. 2000;  45 457-466
• 169 Jones M E, Staples A M, Critchley I et al.. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.  Antimicrob Agents Chemother. 2000;  44 2645-2652
• 170 Gonzalez B E, Hulten K G, Lamberth L, Kaplan S L, Mason Jr E O. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine.  Pediatr Infect Dis J. 2006;  25 301-305
• 171 Jacobs M R, Good C E, Beall B, Bajaksouzian S, Windau A R, Whitney C G. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience.  J Clin Microbiol. 2008;  46 982-990
• 172 Pelton S I, Huot H, Finkelstein J A et al.. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.  Pediatr Infect Dis J. 2007;  26 468-472
• 173 Davidson R J, Melano R, Forward K R. Antimicrobial resistance among invasive isolates of Streptococcus pneumoniae collected across Canada.  Diagn Microbiol Infect Dis. 2007;  59 75-80
• 174 Poulakou G, Katsarolis I, Matthaiopoulou I et al.. Nationwide surveillance of Streptococcus pneumoniae in Greece: patterns of resistance and serotype epidemiology.  Int J Antimicrob Agents. 2007;  30 87-92
• 175 Sahm D F, Karlowsky J A, Kelly L J et al.. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis.  Antimicrob Agents Chemother. 2001;  45 1037-1042
• 176 Jones R N, Sader H S, Fritsche T R, Pottumarthy S. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998–2004).  Diagn Microbiol Infect Dis. 2007;  57 109-116
• 177 Hsieh Y C, Chang K Y, Huang Y C et al.. Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.  Antimicrob Agents Chemother. 2008;  52 2266-2269
• 178 Richter S S, Heilmann K P, Beekmann S E, Miller N J, Rice C L, Doern G V. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.  Clin Infect Dis. 2005;  40 225-235
• 179 Miller M L, Obert C A, Gao G, Daw N C, Flynn P, Tuomanen E. Cephalosporin-resistant pneumococci and sickle cell disease.  Emerg Infect Dis. 2005;  11 1192-1196
• 180 John C C. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.  Clin Infect Dis. 1994;  18 188-193
• 181 Klugman K P, Koornhof H J, Friedland I R. Antibiotic resistance in pneumococcal meningitis.  Lancet. 1992;  340(8816) 437-438
• 182 Ahronheim G A, Reich B, Marks M I. Penicillin-insensitive pneumococci: case report and review.  Am J Dis Child. 1979;  133 187-191
• 183 Howes V J, Mitchell R G. Meningitis due to relatively penicillin-resistant pneumococcus.  BMJ. 1976;  1 996
• 184 Friedland I R, Klugman K P. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis.  Lancet. 1992;  339 405-408
• 185 Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms.  Pediatr Infect Dis J. 2000;  19(5, Suppl) S57-S65
• 186 Dowell S F, Butler J C, Giebink G S et al.. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.  Pediatr Infect Dis J. 1999;  18 1-9
• 187 Kaplan S L, Mason Jr E O, Barson W J et al.. Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics.  Pediatr Infect Dis J. 2001;  20 392-396
• 188 Arditi M, Mason Jr E O, Bradley J S et al.. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use.  Pediatrics. 1998;  102 1087-1097
• 189 Fiore A E, Moroney J F, Farley M M et al.. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance.  Clin Infect Dis. 2000;  30 71-77
• 190 Auburtin M, Porcher R, Bruneel F et al.. Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases.  Am J Respir Crit Care Med. 2002;  165 713-717
• 191 Tan T Q, Schutze G E, Mason Jr E O, Kaplan S L. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.  Antimicrob Agents Chemother. 1994;  38 918-923
• 192 Friedland I R, Klugman K P. Antibiotic-resistant pneumococcal disease in South African children.  Am J Dis Child. 1992;  146 920-923
• 193 Therapy for children with invasive pneumococcal infections. American Academy of Pediatrics Committee on Infectious Diseases.  Pediatrics. 1997;  99 289-299
• 194 Quagliarello V J, Scheld W M. Treatment of bacterial meningitis.  N Engl J Med. 1997;  336 708-716
• 195 Leggiadro R J. The clinical impact of resistance in the management of pneumococcal disease.  Infect Dis Clin North Am. 1997;  11 867-874
• 196 Frankel R E, Virata M, Hardalo C, Altice F L, Friedland G. Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection.  Clin Infect Dis. 1996;  23 577-584
• 197 Kalin M, Ortqvist A, Almela M et al.. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries.  J Infect Dis. 2000;  182 840-847
• 198 Marfin A A, Sporrer J, Moore P S, Siefkin A D. Risk factors for adverse outcome in persons with pneumococcal pneumonia.  Chest. 1995;  107 457-462
• 199 Watanakunakorn C, Greifenstein A, Stroh K et al.. Pneumococcal bacteremia in three community teaching hospitals from 1980 to 1989.  Chest. 1993;  103 1152-1156
• 200 Afessa B, Greaves W L, Frederick W R. Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital.  Clin Infect Dis. 1995;  21 345-351
• 201 Castillo E M, Rickman L S, Brodine S K, Ledbetter E K, Kelly C. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance.  Am J Infect Control. 2000;  28 239-243
• 202 Watanabe H, Sato S, Kawakami K et al.. A comparative clinical study of pneumonia by penicillin-resistant and -sensitive Streptococcus pneumoniae in a community hospital.  Respirology. 2000;  5 59-64
• 203 Moroney J F, Fiore A E, Harrison L H et al.. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance.  Clin Infect Dis. 2001;  33 797-805
• 204 Roson B, Carratala J, Tubau F et al.. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.  Microb Drug Resist. 2001;  7 85-96
• 205 Wu T T, Hsueh P R, Lee L N, Yang P C, Luh K T. Pneumonia caused by penicillin-nonsusceptible Streptococcus pneumoniae: clinical characteristics, prognostic factors, and outcomes.  J Formos Med Assoc. 2000;  99 18-23
• 206 Mufson M A, Chan G, Stanek R J. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started.  Am J Med Sci. 2007;  333 161-167
• 207 Falco V, Almirante B, Jordano Q et al.. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?.  J Antimicrob Chemother. 2004;  54 481-488
• 208 Tleyjeh I M, Tlaygeh H M, Hejal R, Montori V M, Baddour L M. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis.  Clin Infect Dis. 2006;  42 788-797
• 209 Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality.  Crit Care Med. 2004;  32 625-631
• 210 Bradley J S, Connor J D. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics.  Pediatr Infect Dis J. 1991;  10 871-873
• 211 Viladrich P F, Gudiol F, Linares J, Rufi G, Ariza J, Pallares R. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci.  Am J Med. 1988;  84 839-846
• 212 Friedland I R, Shelton S, Paris M et al.. Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis.  Pediatr Infect Dis J. 1993;  12 196-200
• 213 Lonks J R, Durkin M R, Meyerhoff A N, Medeiros A A. Meningitis due to ceftriaxone-resistant Streptococcus pneumoniae .  N Engl J Med. 1995;  332 893-894
• 214 Guibert M, Chahime H, Petit J, Odievre M, Labrune P. Failure of cefotaxime treatment in two children with meningitis caused by highly penicillin-resistant Streptococcus pneumoniae .  Acta Paediatr. 1995;  84 831-833
• 215 Greene G S, Demasi R. Case report: penicillin-resistant pneumococcal meningitis: navigating a therapeutic minefield.  Am J Med Sci. 1996;  311 180-185
• 216 Pacheco T R, Cooper C K, Hardy D J, Betts R F, Bonnez W. Failure of cefotaxime treatment in an adult with Streptococcus pneumoniae meningitis.  Am J Med. 1997;  102 303-305
• 217 Viladrich P F, Cabellos C, Pallares R et al.. High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins.  Antimicrob Agents Chemother. 1996;  40 218-220
• 218 Sacho H, Klugman K P, Koornhof H J, Ruff P. Community-acquired pneumonia in an adult due to a multiply-resistant pneumococcus.  J Infect. 1987;  14 188-189
• 219 Buckingham S C, Brown S P, Joaquin V H. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia.  J Pediatr. 1998;  132 174-176
• 220 Dowell S F, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child.  Clin Infect Dis. 1999;  29 462-463
• 221 Silverstein M, Bachur R, Harper M B. Clinical implications of penicillin and ceftriaxone resistance among children with pneumococcal bacteremia.  Pediatr Infect Dis J. 1999;  18 35-41
• 222 Klugman K P, Lonks J R. Hidden epidemic of macrolide-resistant pneumococci.  Emerg Infect Dis. 2005;  11 802-807
• 223 Geslin P, Buu-Hoi A, Fremaux A, Acar J F. Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970–1990.  Clin Infect Dis. 1992;  15 95-98
• 224 Verhaegen J, Glupczynski Y, Verbist L et al.. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980–1993.  Clin Infect Dis. 1995;  20 1339-1345
• 225 Zhanel G G, Dueck M, Hoban D J et al.. Review of macrolides and ketolides: focus on respiratory tract infections.  Drugs. 2001;  61 443-498
• 226 Edelstein P H. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes.  Clin Infect Dis. 2004;  38(Suppl 4) S322-S327
• 227 Tait-Kamradt A, Davies T, Appelbaum P C et al.. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.  Antimicrob Agents Chemother. 2000;  44 3395-3401
• 228 Cerda Zolezzi P, Laplana L M, Calvo C R, Cepero P G, Erazo M C, Gomez-Lus R. Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2004;  48 3462-3467
• 229 Wierzbowski A K, Swedlo D, Boyd D et al.. Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002.  Antimicrob Agents Chemother. 2005;  49 1257-1261
• 230 Farrell D J, Jenkins S G. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001–2002.  J Antimicrob Chemother. 2004;  54(Suppl 1) i17-i22
• 231 Amezaga M R, Carter P E, Cash P, McKenzie H. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites.  J Clin Microbiol. 2002;  40 3313-3318
• 232 Montanari M P, Mingoia M, Cochetti I, Varaldo P E. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy.  J Clin Microbiol. 2003;  41 428-431
• 233 Del Grosso M, Iannelli F, Messina C et al.. Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae .  J Clin Microbiol. 2002;  40 774-778
• 234 Canu A, Malbruny B, Coquemont M, Davies T A, Appelbaum P C, Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2002;  46 125-131
• 235 Shortridge V D, Doern G V, Brueggemann A B, Beyer J M, Flamm R K. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994–1995.  Clin Infect Dis. 1999;  29 1186-1188
• 236 Farrell D J, Douthwaite S, Morrissey I et al.. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999–2000 study.  Antimicrob Agents Chemother. 2003;  47 1777-1783
• 237 Morosini M I, Loza E, del Campo R, Almaraz F, Baquero F, Canton R. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.  Antimicrob Agents Chemother. 2003;  47 2692-2695
• 238 Bingen E, Doit C, Loukil C et al.. Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections.  Antimicrob Agents Chemother. 2003;  47 2345-2347
• 239 Tiemei Z, Xiangqun F, Youning L. Resistance phenotypes and genotypes of erythromycin-resistant Streptococcus pneumoniae isolates in Beijing and Shenyang, China.  Antimicrob Agents Chemother. 2004;  48 4040-4041
• 240 Isozumi R, Ito Y, Ishida T et al.. Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan.  J Clin Microbiol. 2007;  45 1440-1446
• 241 Jones M E, Sahm D F, Martin N et al.. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997–1998 respiratory season.  Antimicrob Agents Chemother. 2000;  44 462-466
• 242 Pihlajamaki M, Jalava J, Huovinen P, Kotilainen P. Antimicrobial resistance of invasive pneumococci in Finland in 1999–2000.  Antimicrob Agents Chemother. 2003;  47 1832-1835
• 243 Reinert R R, Al-Lahham A, Lemperle M et al.. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.  J Antimicrob Chemother. 2002;  49 61-68
• 244 Tait-Kamradt A, Davies T, Cronan M, Jacobs M R, Appelbaum P C, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.  Antimicrob Agents Chemother. 2000;  44 2118-2125
• 245 Pihlajamaki M, Kataja J, Seppala H et al.. Ribosomal mutations in Streptococcus pneumoniae clinical isolates.  Antimicrob Agents Chemother. 2002;  46 654-658
• 246 Dias R, Canica M. Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14.  J Antimicrob Chemother. 2004;  54 1035-1039
• 247 Sweeney M T, Zurenko G E. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms.  Antimicrob Agents Chemother. 2003;  47 1902-1906
• 248 Anderegg T R, Sader H S, Fritsche T R, Ross J E, Jones R N. Trends in linezolid susceptibility patterns: report from the 2002–2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.  Int J Antimicrob Agents. 2005;  26 13-21
• 249 Metlay J P, Fishman N O, Joffe M M, Kallan M J, Chittams J L, Edelstein P H. Macrolide resistance in adults with bacteremic pneumococcal pneumonia.  Emerg Infect Dis. 2006;  12 1223-1230
• 250 Barkai G, Greenberg D, Givon-Lavi N, Dreifuss E, Vardy D, Dagan R. Community prescribing and resistant Streptococcus pneumoniae .  Emerg Infect Dis. 2005;  11 829-837
• 251 Doern G V, Brown S D. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000–01.  J Infect. 2004;  48 56-65
• 252 Ortega M, Marco F, Soriano A, Garcia E, Martinez J A, Mensa J. Lack of vancomycin tolerance in Streptococcus pneumoniae strains isolated in Barcelona, Spain, from 1999 to 2001.  Antimicrob Agents Chemother. 2003;  47 1976-1978
• 253 Kanavaki S, Karabela S, Marinis E, Legakis N J. Antibiotic resistance of clinical isolates of Streptococcus pneumoniae in Greece.  J Clin Microbiol. 1994;  32 3056-3058
• 254 Ednie L M, Visalli M A, Jacobs M R, Appelbaum P C. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.  Antimicrob Agents Chemother. 1996;  40 1950-1952
• 255 Friedland I R, McCracken Jr G H. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae .  N Engl J Med. 1994;  331 377-382
• 256 Arri S J, Fluegge K, Mueller U, Berner R. Antibiotic resistance patterns among respiratory pathogens at a German university children's hospital over a period of 10 years.  Eur J Pediatr. 2006;  165 9-13
• 257 Ip M, Lyon D J, Yung R W, Chan C, Cheng A F. Macrolide resistance in Streptococcus pneumoniae in Hong Kong.  Antimicrob Agents Chemother. 2001;  45 1578-1580
• 258 Hsueh P R, Luh K T. Antimicrobial resistance in Streptococcus pneumoniae, Taiwan.  Emerg Infect Dis. 2002;  8 1487-1491
• 259 Bergan T, Gaustad P, Hoiby E A et al.. Antibiotic resistance of pneumococci in Norway.  Int J Antimicrob Agents. 1998;  10 77-81
• 260 Berner R. Antimicrobial susceptibility patterns of Streptococcus pneumoniae and Haemophilus influenzae in a German pediatric hospital, 1993 to 1997.  Pediatr Infect Dis J. 1998;  17 925-927
• 261 Reinert R R, Queck A, Kaufhold A, Kresken M, Lutticken R. Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992–1994.  Clin Infect Dis. 1995;  21 1398-1401
• 262 Mittermayer H, Jebelean C, Binder L, Haditsch M, Watschinger R. Antibiotic susceptibility of pneumococci isolated in Austria over a four-year period.  Eur J Clin Microbiol Infect Dis. 1996;  15 817-820
• 263 Boswell T C, Frodsham D, Nye K J, Smith E G. Antibiotic resistance and serotypes of Streptococcus pneumoniae at Birmingham Public Health Laboratory, 1989–94.  J Infect. 1996;  33 17-22
• 264 Aszkenasy O M, George R C, Begg N T. Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992.  Commun Dis Rep CDR Rev. 1995;  5 R45-R50
• 265 Klugman K P, Capper T, Widdowson C A, Koornhof H J, Moser W. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates.  J Antimicrob Chemother. 1998;  42 729-734
• 266 Dagan R, Melamed R, Muallem M, Piglansky L, Yagupsky P. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines.  J Infect Dis. 1996;  174 1352-1355
• 267 Barry A L, Pfaller M A, Fuchs P C, Packer R R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.  Antimicrob Agents Chemother. 1994;  38 2419-2425
• 268 Mason Jr E O, Lamberth L B, Wald E R, Bradley J S, Barson W J, Kaplan S L. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.  Antimicrob Agents Chemother. 2003;  47 166-169
• 269 Karchmer A W. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US—an update.  Clin Infect Dis. 2004;  39(Suppl 3) S142-S150
• 270 Farrell D J, File T M, Jenkins S G. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.  J Clin Microbiol. 2007;  45 290-293
• 271 Johnston N J, De Azavedo J C, Kellner J D, Low D E. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 1998;  42 2425-2426
• 272 Zhanel G G, Karlowsky J A, Palatnick L, Vercaigne L, Low D E, Hoban D J. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group.  Antimicrob Agents Chemother. 1999;  43 2504-2509
• 273 Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: findings of the Alexander Project 1992–1996.  J Chemother. 1999;  11(Suppl 1) 5-21
• 274 Louie M, Louie L, Papia G, Talbot J, Lovgren M, Simor A E. Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae serotypes in Canada.  J Infect Dis. 1999;  179 892-900
• 275 Duchin J S, Breiman R F, Diamond A et al.. High prevalence of multidrug-resistant Streptococcus pneumoniae among children in a rural Kentucky community.  Pediatr Infect Dis J. 1995;  14 745-750
• 276 Lonks J R, Garau J, Gomez L et al.. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae .  Clin Infect Dis. 2002;  35 556-564
• 277 Van Kerkhoven D, Peetermans W E, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams.  J Antimicrob Chemother. 2003;  51 691-696
• 278 McGee L, Klugman K P, Wasas A, Capper T, Brink A. Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa.  Antimicrob Agents Chemother. 2001;  45 1595-1598
• 279 McGee L, Wang H, Wasas A, Huebner R, Chen M, Klugman K P. Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones.  Microb Drug Resist. 2001;  7 55-63
• 280 Ko K S, Song J H. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains erm(B) and mef(A) genes.  J Infect Dis. 2004;  190 739-747
• 281 Farrell D J, Morrissey I, Bakker S, Morris L, Buckridge S, Felmingham D. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance.  J Clin Microbiol. 2004;  42 764-768
• 282 Musher D M, Dowell M E, Shortridge V D et al.. Emergence of macrolide resistance during treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  346 630-631
• 283 Rzeszutek M, Wierzbowski A, Hoban D J, Conly J, Bishai W, Zhanel G G. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae .  Int J Antimicrob Agents. 2004;  24 95-104
• 284 Martinez J A, Horcajada J P, Almela M et al.. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.  Clin Infect Dis. 2003;  36 389-395
• 285 Waterer G W, Somes G W, Wunderink R G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.  Arch Intern Med. 2001;  161 1837-1842
• 286 Zhanel G G, Johanson C, Laing N, Hisanaga T, Wierzbowski A, Hoban D J. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.  Antimicrob Agents Chemother. 2005;  49 1943-1948
• 287 Lonks J R, Goldmann D A. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.  Clin Infect Dis. 2005;  40 1657-1664
• 288 Syrogiannopoulos G A, Grivea I N, Ednie L M et al.. Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A) .  Antimicrob Agents Chemother. 2003;  47 2699-2702
• 289 Jorgensen J H, Crawford S A, McElmeel M L, Whitney C G. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2004;  48 605-607
• 290 Morrissey I, Farrell D J, Bakker S, Buckridge S, Felmingham D. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong.  Antimicrob Agents Chemother. 2003;  47 1433-1435
• 291 Stratton C W, Brown S D. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000–2001.  Clin Ther. 2004;  26 522-530
• 292 Farrell D J, Felmingham D. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.  Antimicrob Agents Chemother. 2004;  48 1882-1884
• 293 Perez-Trallero E, Marimon J M, Iglesias L, Larruskain J. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.  Emerg Infect Dis. 2003;  9 1159-1162
• 294 Al-Lahham A, Appelbaum P C, van der Linden M, Reinert R R. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.  Antimicrob Agents Chemother. 2006;  50 3897-3900
• 295 Zervos M J, Hershberger E, Nicolau D P et al.. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000.  Clin Infect Dis. 2003;  37 1643-1648
• 296 Paterson D L, Mulazimoglu L, Casellas J M et al.. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.  Clin Infect Dis. 2000;  30 473-478
• 297 Saurina G, Quale J M, Manikal V M, Oydna E, Landman D. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns.  J Antimicrob Chemother. 2000;  45 895-898
• 298 Thomson C J. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.  J Antimicrob Chemother. 1999;  43(Suppl A) 31-40
• 299 de la Campa A G, Ferrandiz M J, Tubau F, Pallares R, Manresa F, Linares J. Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis.  Antimicrob Agents Chemother. 2003;  47 1419-1422
• 300 Perez-Trallero E, Garcia-Arenzana J M, Jimenez J A, Peris A. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.  Eur J Clin Microbiol Infect Dis. 1990;  9 905-906
• 301 Ena J, Lopez-Perezagua M M, Martinez-Peinado C, Cia-Barrio M A, Ruiz-Lopez I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones.  Diagn Microbiol Infect Dis. 1998;  30 103-107
• 302 Zhanel G G, Ennis K, Vercaigne L et al.. A critical review of the fluoroquinolones: focus on respiratory infections.  Drugs. 2002;  62 13-59
• 303 Adam H J, Schurek K N, Nichol K A et al.. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.  Antimicrob Agents Chemother. 2007;  51 198-207
• 304 Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.  Antimicrob Agents Chemother. 2002;  46 522-524
• 305 Fernandez-Moreira E, Balas D, Gonzalez I, de la Campa A G. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.  Microb Drug Resist. 2000;  6 259-267
• 306 Balsalobre L, de la Campa A G. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.  Antimicrob Agents Chemother. 2008;  52 822-830
• 307 Pan X S, Fisher L M. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.  Antimicrob Agents Chemother. 1999;  43 1129-1136
• 308 Davies T A, Evangelista A, Pfleger S, Bush K, Sahm D F, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.  Antimicrob Agents Chemother. 2002;  46 119-124
• 309 Smith H J, Walters M, Hisanaga T, Zhanel G G, Hoban D J. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.  Antimicrob Agents Chemother. 2004;  48 3954-3958
• 310 Martinez-Garriga B, Vinuesa T, Hernandez-Borrell J, Vinas M. The contribution of efflux pumps to quinolone resistance in Streptococcus pneumoniae clinical isolates.  Int J Med Microbiol. 2007;  297 187-195
• 311 Jumbe N L, Louie A, Miller M H et al.. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2006;  50 310-317
• 312 Ho P L, Tse W S, Tsang K W et al.. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.  Clin Infect Dis. 2001;  32 701-707
• 313 Perez-Trallero E, Marimon J M, Gonzalez A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease.  Clin Infect Dis. 2005;  41 560-564
• 314 Kupronis B A, Richards C L, Whitney C G. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community.  J Am Geriatr Soc. 2003;  51 1520-1525
• 315 Deshpande L M, Sader H S, Debbia E, Nicoletti G, Fadda G, Jones R N. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001–2004).  Diagn Microbiol Infect Dis. 2006;  54 157-164
• 316 Johnson A P, Sheppard C L, Harnett S J et al.. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England.  J Antimicrob Chemother. 2003;  52 953-960
• 317 Goldsmith C E, Moore J E, Murphy P G, Ambler J E. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.  J Antimicrob Chemother. 1998;  41 420-421
• 318 Schmitz F J, Perdikouli M, Beeck A, Verhoef J, Fluit A C. Molecular surveillance of macrolide, tetracycline and quinolone resistance mechanisms in 1191 clinical European Streptococcus pneumoniae isolates.  Int J Antimicrob Agents. 2001;  18 433-436
• 319 Nagai K, Appelbaum P C, Davies T A et al.. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and Eastern European countries.  Antimicrob Agents Chemother. 2002;  46 371-377
• 320 Jones M E, Blosser-Middleton R S, Critchley I A, Karlowsky J A, Thornsberry C, Sahm D F. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001.  Clin Microbiol Infect. 2003;  9 590-599
• 321 Garcia-Rey C, Aquilar L, Baquero F. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain.  Antimicrob Agents Chemother. 2000;  44 3481-3482
• 322 von Gottberg A, Klugman K P, Cohen C et al.. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.  Lancet. 2008;  371 1108-1113
• 323 Gosbell I B, Fernandes L A, Fernandes C J. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.  Pathology. 2006;  38 343-348
• 324 Song J H, Oh W S, Kang C I et al.. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens.  Int J Antimicrob Agents. 2008;  31 107-114
• 325 Yamaguchi K, Ohno A. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002.  Diagn Microbiol Infect Dis. 2005;  52 135-143
• 326 Chiu S S, Ho P L, Chow F K, Yuen K Y, Lau Y L. Nasopharyngeal carriage of antimicrobial-resistant Streptococcus pneumoniae among young children attending 79 kindergartens and day care centers in Hong Kong.  Antimicrob Agents Chemother. 2001;  45 2765-2770
• 327 Jones R N, Pfaller M A. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997–1999).  J Clin Microbiol. 2000;  38 4298-4299
• 328 Pottumarthy S, Fritsche T R, Sader H S, Stilwell M G, Jones R N. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002–2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.  Int J Antimicrob Agents. 2005;  25 282-289
• 329 Quale J, Landman D, Ravishankar J, Flores C, Bratu S. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep.  Emerg Infect Dis. 2002;  8 594-597
• 330 Bhavnani S, Hammel J P, Jones R N et al.. Relationship between increased levofloxacin use and decreased susceptibility to Streptococcus pneumonia: report from the ARREST Program [abstract K-1397]. In: Program and Abstracts of the 43rd International Conference on Antimicrobial QAgents and Chemotherapy Washington, DC; American Society for Microbiology 2003: 383
• 331 Lim S, Bast D, McGeer A, de Azavedo J, Low D E. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.  Emerg Infect Dis. 2003;  9 833-837
• 332 Davies T A, Yee Y C, Bush K, Sahm D, Evangelista A, Goldschmidt R. Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae .  Microb Drug Resist. 2008;  14 187-196
• 333 Perez-Trallero E, Garcia-Rey C, Martin-Sanchez A M, Aguilar L, Garcia-de-Lomas J, Ruiz J. Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain.  Antimicrob Agents Chemother. 2002;  46 2665-2667
• 334 Zhanel G G, Walkty A, Nichol K, Smith H, Noreddin A, Hoban D J. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.  Diagn Microbiol Infect Dis. 2003;  45 63-67
• 335 Davies T A, Yee Y C, Goldschmidt R, Bush K, Sahm D F, Evangelista A. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999–2003).  J Antimicrob Chemother. 2006;  57 437-442
• 336 Pletz M W, Shergill A P, McGee L, Beall B, Whitney C G, Klugman K P. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States.  Antimicrob Agents Chemother. 2006;  50 1561-1563
• 337 McGee L, Goldsmith C E, Klugman K P. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones.  J Antimicrob Chemother. 2002;  49 173-176
• 338 Canton R, Morosini M, Enright M C, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.  J Antimicrob Chemother. 2003;  52 944-952
• 339 Perez-Trallero E, Marimon J M, Gonzalez A, Iglesias L. Spain14–5 international multiresistant Streptococcus pneumoniae clone resistant to fluoroquinolones and other families of antibiotics.  J Antimicrob Chemother. 2003;  51 715-719
• 340 Carter R J, Sorenson G, Heffernan R et al.. Failure to control an outbreak of multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: emergence and ongoing transmission of a fluoroquinolone-resistant strain.  Infect Control Hosp Epidemiol. 2005;  26 248-255
• 341 Fry A M, Udeagu C C, Soriano-Gabarro M et al.. Persistence of fluoroquinolone-resistant, multidrug-resistant Streptococcus pneumoniae in a long-term-care facility: efforts to reduce intrafacility transmission.  Infect Control Hosp Epidemiol. 2005;  26 239-247
• 342 Ambrose P G, Bhavnani S M, Owens Jr R C. Clinical pharmacodynamics of quinolones.  Infect Dis Clin North Am. 2003;  17 529-543
• 343 Jones R N, Rubino C M, Bhavnani S M, Ambrose P G. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.  Antimicrob Agents Chemother. 2003;  47 292-296
• 344 Allen G P, Kaatz G W, Rybak M J. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.  Antimicrob Agents Chemother. 2003;  47 2606-2614
• 345 Blondeau J M, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2001;  45 433-438
• 346 Smith H J, Noreddin A M, Siemens C G et al.. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.  Antimicrob Agents Chemother. 2004;  48 3630-3635
• 347 Bast D J, Low D E, Duncan C L et al.. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.  Antimicrob Agents Chemother. 2000;  44 3049-3054
• 348 Hovde L B, Simonson D A, Rotschafer J C. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.  Diagn Microbiol Infect Dis. 2008;  60 295-299
• 349 Kays M B, Smith D W, Wack M E, Denys G A. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.  Pharmacotherapy. 2002;  22 395-399
• 350 Ross J J, Worthington M G, Gorbach S L. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.  N Engl J Med. 2002;  347 65-67 author reply 67
• 351 Anderson K B, Tan J S, File Jr T M, DiPersio J R, Willey B M, Low D E. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.  Clin Infect Dis. 2003;  37 376-381
• 352 Pletz M W, McGee L, Burkhardt O, Lode H, Klugman K P. Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy.  Eur J Clin Microbiol Infect Dis. 2005;  24 58-60
• 353 Roson B, Carratala J, Fernandez-Sabe N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia.  Arch Intern Med. 2004;  164 502-508
• 354 Fuller J D, Low D E. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.  Clin Infect Dis. 2005;  41 118-121
• 355 Fluit A C, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline.  Antimicrob Agents Chemother. 2005;  49 1636-1638
• 356 Izdebski R, Sadowy E, Fiett J, Grzesiowski P, Gniadkowski M, Hryniewicz W. Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.  Antimicrob Agents Chemother. 2007;  51 1155-1163
• 357 Erdem H, Pahsa A. Antibiotic resistance in pathogenic Streptococcus pneumoniae isolates in Turkey.  J Chemother. 2005;  17 25-30
• 358 Jenkins S G, Farrell D J, Patel M, Lavin B S. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000–2003: PROTEKT US years 1–3.  J Infect. 2005;  51 355-363
• 359 Wierzbowski A, Nichol K, DeCorby M, Hoban D J, Zhanel G. Streptococcus pneumoniae in Canadian intensive care units: prevalence and antibiotic resistance results obtained during 2005 and 2006 Canadian Intensive Care Unit Surveillance Study (CAN-ICU). Vancouver, BC; Association of Medical Microbiology and Infectious Diseases of Canada (AMMI) 2008
• 360 Karpanoja P, Nyberg S T, Bergman M et al.. Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis .  Antimicrob Agents Chemother. 2008;  52 2480-2485
• 361 Zarakolu P, Soyletir G, Gur D, Unal S. Antimicrobial resistance patterns of respiratory pathogens: a local report from Turkey.  Clin Microbiol Infect. 2003;  9 1257-1258
• 362 Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae .  Nature. 1999;  399 590-593
• 363 McCullers J A, English B K, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis.  J Infect Dis. 2000;  181 369-373
• 364 Henriques Normark B, Novak R, Ortqvist A, Kallenius G, Tuomanen E, Normark S. Clinical isolates of Streptococcus pneumoniae that exhibit tolerance of vancomycin.  Clin Infect Dis. 2001;  32 552-558
• 365 Gillis L M, White H D, Whitehurst A, Sullivan D C. Vancomycin-tolerance among clinical isolates of Streptococcus pneumoniae in Mississippi during 1999–2001.  Am J Med Sci. 2005;  330 65-68
• 366 Cha R, Rybak M J. Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model.  Antimicrob Agents Chemother. 2003;  47 1984-1987
• 367 Rodriguez-Cerrato V, McCoig C C, Saavedra J et al.. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.  Antimicrob Agents Chemother. 2003;  47 211-215
• 368 Martinez-Lacasa J, Cabellos C, Martos A et al.. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis.  J Antimicrob Chemother. 2002;  49 507-513
• 369 Linares J, Pallares R, Alonso T et al.. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979–1990).  Clin Infect Dis. 1992;  15 99-105
• 370 Marchese A, Mannelli S, Tonoli E, Gorlero F, Toni M, Schito G C. Prevalence of antimicrobial resistance in Streptococcus pneumoniae circulating in Italy: results of the Italian Epidemiological Observatory Survey (1997–1999).  Microb Drug Resist. 2001;  7 277-287
• 371 Ferrandiz M J, Ardanuy C, Linares J et al.. New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitals.  Antimicrob Agents Chemother. 2005;  49 2237-2245
• 372 Restrepo M I, Velez J A, McElmeel M L, Whitney C G, Jorgensen J H. Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae .  Antimicrob Agents Chemother. 2003;  47 2974-2977
• 373 Spangler S K, Jacobs M R, Appelbaum P C. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.  Antimicrob Agents Chemother. 1996;  40 481-484
• 374 Fluit A C, Schmitz F J, Verhoef J, Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.  Antimicrob Agents Chemother. 2004;  48 1007-1011
• 375 Cottagnoud P, Pfister M, Acosta F et al.. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.  Antimicrob Agents Chemother. 2004;  48 3928-3933
• 376 Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Tauber M G. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.  Antimicrob Agents Chemother. 2003;  47 1943-1947
• 377 Cabellos C, Fernandez A, Maiques J M et al.. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.  Antimicrob Agents Chemother. 2003;  47 1907-1911
• 378 Zhanel G G, Homenuik K, Nichol K et al.. The glycylcyclines: a comparative review with the tetracyclines.  Drugs. 2004;  64 63-88
• 379 Denys G A, Koch K M, Dowzicky M J. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.  Am J Infect Control. 2007;  35 521-526
• 380 Hausdorff W P, Bryant J, Paradiso P R, Siber G R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.  Clin Infect Dis. 2000;  30 100-121
• 381 Feikin D R, Klugman K P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines.  Clin Infect Dis. 2002;  35 547-555
• 382 Whitney C G, Farley M M, Hadler J et al.. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.  N Engl J Med. 2003;  348 1737-1746
• 383 Pelton S I. The decline in invasive pneumococcal disease.  Pediatrics. 2004;  113(3 Pt 1) 617-618
• 384 Kaplan S L, Mason Jr E O, Wald E R et al.. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.  Pediatrics. 2004;  113(3 Pt 1) 443-449
• 385 Talbot T R, Poehling K A, Hartert T V et al.. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine.  Clin Infect Dis. 2004;  39 641-648
• 386 Dagan R, Givon-Lavi N, Zamir O et al.. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers.  J Infect Dis. 2002;  185 927-936
• 387 Eskola J, Kilpi T, Palmu A et al.. Efficacy of a pneumococcal conjugate vaccine against acute otitis media.  N Engl J Med. 2001;  344 403-409
• 388 Temime L, Guillemot D, Boelle P Y. Short- and long-term effects of pneumococcal conjugate vaccination of children on penicillin resistance.  Antimicrob Agents Chemother. 2004;  48 2206-2213
• 389 Regelmann W E. A pain in the ear: what has the 7-valent conjugated pneumococcal vaccine done to reduce the incidence of acute otitis media?.  Clin Infect Dis. 2005;  40 1745-1747
• 390 Park S Y, Moore M R, Bruden D L et al.. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children.  Pediatr Infect Dis J. 2008;  27 335-340
• 391 McGee L. The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae .  Curr Opin Microbiol. 2007;  10 473-478
• 392 Choi E H, Kim S H, Kim S J et al.. Streptococcus pneumoniae serotype 19A in children, South Korea.  Emerg Infect Dis. 2008;  14 275-281
• 393 Mera R, Miller L A, Fritsche T R, Jones R N. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine.  Microb Drug Resist. 2008;  14 101-107
• 394 Hanage W P, Huang S S, Lipsitch M et al.. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era.  J Infect Dis. 2007;  195 347-352